Semiconductor-Based Nanopore Sequencing Platform Developed for Molecular Diagnostics
By LabMedica International staff writers Posted on 24 Jan 2012 |
A startup company is developing a semiconductor-based nanopore-sequencing platform that will be used for molecular diagnostic applications.
Genia, the Mountain View (CA, USA)-based startup has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.
Stefan Roever, CEO and founder of the company declined to provide a commercialization timeline for the system or details regarding expected read length or accuracy, but noted that he believes the platform will be able to sequence genomes at a cost "one order of magnitude less" than other single-molecule systems.
He described the system as a "single-molecule electrical detection sequencing platform," and said that the company expects it to be useful for targeted resequencing and molecular diagnostics that involve both human genomics and viral or bacterial DNA.
A number of other firms are developing nanopore sequencing systems, but Stephen Roever said that Genia's focus on the underlying chip platform sets it apart from competitors.
"We focused on operationalizing the nanopores," Stephen Roever said. "We essentially developed a way to create what are effectively lipid bilayer nanopore complexes, so the biological nanopore is a transmembrane protein that's suspended in a lipid bilayer."
The company has developed a way to "automatically set up whole arrays of [the nanopores] on the surface of a semiconductor chip and integrated circuit," ultimately making a "very complicated" process "massively scalable."
"We have a working platform and chip, and we have the basic building blocks on the biochemistry side. The next step is to take those and assemble them into a robust chemistry," said Mr. Roever. "That's where the focus is going to be and there's a significant amount of work still to be done there."
Genia, the Mountain View (CA, USA)-based startup has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.
Stefan Roever, CEO and founder of the company declined to provide a commercialization timeline for the system or details regarding expected read length or accuracy, but noted that he believes the platform will be able to sequence genomes at a cost "one order of magnitude less" than other single-molecule systems.
He described the system as a "single-molecule electrical detection sequencing platform," and said that the company expects it to be useful for targeted resequencing and molecular diagnostics that involve both human genomics and viral or bacterial DNA.
A number of other firms are developing nanopore sequencing systems, but Stephen Roever said that Genia's focus on the underlying chip platform sets it apart from competitors.
"We focused on operationalizing the nanopores," Stephen Roever said. "We essentially developed a way to create what are effectively lipid bilayer nanopore complexes, so the biological nanopore is a transmembrane protein that's suspended in a lipid bilayer."
The company has developed a way to "automatically set up whole arrays of [the nanopores] on the surface of a semiconductor chip and integrated circuit," ultimately making a "very complicated" process "massively scalable."
"We have a working platform and chip, and we have the basic building blocks on the biochemistry side. The next step is to take those and assemble them into a robust chemistry," said Mr. Roever. "That's where the focus is going to be and there's a significant amount of work still to be done there."
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear